Target Discovery
Target discovery is the foundational and most critical upstream link in modern pharmaceutical R&D, directly determining the success rate, specificity, and safety of subsequent lead compound screening and clinical candidate development. Unclear disease-related molecular mechanisms and unreliable target validation often lead to high R&D costs and late-stage project failure. As a high-end biopharmaceutical service brand under STEMart, PharmaAnalytica integrates multi-omics, gene editing, molecular interaction, and high-throughput profiling core capabilities to build a fully covered, one-stop target discovery technology platform. We support forward and reverse target mining for small molecules, biologics, and precision therapy drugs, efficiently screening highly druggable, disease-causal candidate targets. Our services fully adapt to early exploratory research, target verification, and preclinical layout of pharmaceutical enterprises, helping clients shorten R&D cycles, reduce trial-and-error costs, and quickly lock core therapeutic targets for new drug pipelines.
Specialized Target Discovery Services
Genome-Wide Association Study (GWAS)
Our GWAS service adopts large-scale population genomic big data correlation analysis technology to systematically screen genetic variation loci closely linked to complex disease phenotypes across the whole genome. We use high-density genotyping and bioinformatics statistical modeling to mine susceptibility genes and key regulatory loci associated with pathological processes, realizing forward screening of potential therapeutic targets from a genetic perspective. Combined with clinical cohort phenotypic data, we complete target preliminary association verification, providing reliable genetic-level evidence for subsequent functional validation and drug mechanism research.
CRISPR-Cas9 Screening
We perform high-throughput genome-wide CRISPR-Cas9 gene perturbation screening based on optimized sgRNA library design and stable cell line construction. The platform conducts gene knockout, activation or inhibition interference in disease cell models, and monitors phenotypic changes such as cell proliferation, apoptosis and metabolic response in real time. Through high-throughput sequencing and data deconvolution analysis, we rapidly screen key functional genes that regulate disease phenotypes, achieve high-confidence reverse target identification, and support functional preliminary verification of oncological, inflammatory and metabolic disease targets.
RNA Interference (RNAi) Screening
Our RNAi high-throughput screening service uses chemically synthesized siRNA and shRNA libraries to efficiently and specifically silence target gene expression in in vitro cell models. We adopt multi-well plate automated liquid handling systems to build standardized high-throughput screening workflows, observe continuous changes in cell biological phenotypes after gene silencing, and combine intelligent imaging analysis to quantitatively evaluate gene functional correlations. The method features low interference and high operability, suitable for rapid primary screening of large batches of candidate target genes in early drug research.
Mass Spectrometry (MS)-Based Proteomics
We employ high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) systems to conduct full-quantitative proteomic profiling of disease tissues, cell models and pathological samples. The service covers global protein expression differential analysis, pathway enrichment and protein network interaction mapping. We accurately screen differentially expressed functional proteins closely related to disease occurrence and development, clarify abnormal regulatory pathways at the protein level, and provide direct molecular candidate targets for subsequent drug mechanism research and downstream molecular docking design.
Activity-Based Protein Profiling (ABPP)
ABPP is a functional activity-oriented target capture technology we professionally deploy. We use specific activity-based chemical probes to specifically label active functional proteins in complex biological samples in situ, without interfering with protein expression levels. By coupling enrichment and mass spectrometry identification, we efficiently capture functionally activated key enzymes and signaling proteins in pathological states. It effectively filters invalid low-expression proteins, precisely locks functionally druggable active targets, and greatly improves the efficiency of subsequent compound screening.
Affinity Purification-Mass Spectrometry (AP-MS)
Our AP-MS service takes small-molecule candidate compounds or known active ligands as baits, couples with specific affinity purification tags, and captures endogenous binding proteins in real physiological cell lysates. After non-specific impurity washing and specific elution, combined with high-precision mass spectrometry identification, we accurately reverse-screen direct binding target proteins of active molecules. The whole process features high specificity and low background, perfectly verifying the molecular interaction relationship between lead compounds and potential targets.
Thermal Proteome Profiling (TPP)
We adopt the latest thermal stability shift technology to carry out label-free global target verification. After incubating small-molecule compounds with living cells or tissue lysates, we set gradient temperature heating to induce protein denaturation and precipitation. Combined with quantitative mass spectrometry, we analyze the thermal stability changes of all proteins, judge the direct binding relationship between compounds and targets according to stability differences, realize high-throughput, high-reliability in-situ target verification, and strongly support target druggability evaluation.
Target-Responsive Accessibility Profiling(TRAP)
We adopt advanced Target-Responsive Accessibility Profiling (TRAP) chemoproteomic technology to identify drug-protein interactions based on lysine residue accessibility changes. Small-molecule binding induces protein conformational shifts and steric shielding, altering lysine exposure. We use isotope-coded formaldehyde and BPC for specific dimethylation labeling with stable mass shift detection. Combined with quantitative mass spectrometry, we compare labeling differences, calculate TRAP ratios, and precisely identify direct and allosteric target proteins for high-confidence drug target validation.
Protein Microarray
We employ high-density full-proteome protein microarray chips with high-throughput parallel reaction detection conditions. The microarray covers thousands of human full-length functional proteins, enabling one-stop high-throughput screening of molecular interactions such as protein-small molecule binding, protein-protein interaction and antigen-antibody specific binding. The platform features fast detection speed and high repeatability, suitable for large-scale preliminary screening of candidate target molecules and rapid verification of target-ligand specific binding efficiency in the early stage of drug development.
Why Choose PharmaAnalytica?
Interdisciplinary Expert R&D Team
PharmaAnalytica gathers seasoned interdisciplinary professionals across genomics, proteomics, chemoproteomics and bioinformatics. With abundant hands-on experience in early pharmaceutical target mining and high-throughput screening, the team efficiently solves technical bottlenecks and delivers scientific, project-aligned experimental design for all target discovery workflows.
Integrated Full-Coverage Technical Platform
We operate a full in-house closed-loop target discovery platform, covering gene editing, RNA interference, multi-omics mass spectrometry and chemoproteomic profiling. No external outsourcing is involved, ensuring stable experimental quality, reliable data security and shortened R&D cycles for pharmaceutical target research projects.
Highly Customized Target Discovery Solutions
We tailor flexible, personalized target discovery schemes for diverse therapeutic areas, including oncology, inflammation, neurology and rare diseases. We reasonably adjust screening intensity, sample throughput and analytical depth to perfectly match clients’ different R&D schedules, budget plans and phased target verification demands.
Standardized, Traceable and Compliant Data Delivery
All operations comply with unified standardized laboratory management norms, with complete raw experimental data, mass spectrum records and bioinformatics files fully retained. We provide traceable, audit-ready analytical reports that fully meet enterprise internal reviews and preclinical regulatory submission requirements.
In summary, equipped with a complete technical ecosystem and professional R&D capabilities, PharmaAnalytica, as a reliable brand under STEMart, provides high-efficiency, high-accuracy, and fully compliant one-stop target discovery services, strongly supporting global pharmaceutical enterprises to accelerate innovative drug research and pipeline optimization.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
